Newman: Where Musk has cut the most so far
Published On Feb 19, 2025, 4:30 PM
Elon Musk's government efficiency commission, known as the DOGE commission, has begun its work of cutting the federal budget, claiming to have saved billions through canceled contracts, mostly affecting agencies like USAID and the Department of Education. However, there are questions about the true nature of these 'savings,' as many cuts involve contracts that would not result in immediate financial relief. The situation has led to concerns about potential job losses among federal workers and fears of a recession in areas reliant on federal employment. Investors are watching closely as the reality of these budget cuts and staff reductions could have broader economic implications.
Stock Forecasts
CVNA
Negative
The ongoing cuts to federal spending and potential layoffs of government employees may lead to reduced consumer spending, which could impact various sectors negatively. Companies that rely heavily on consumers from federal jobs or government contracts might face downturns. Moreover, if the situation escalates to a recession, it would likely affect many businesses. Investors should monitor companies connected to government contracts, particularly in sectors like construction and technology.
HIMS
Positive
Conversely, companies that focus on cost-cutting solutions or lean operational efficiencies may experience positive momentum as federal agencies look to streamline their processes. Investors might find opportunities in firms that can capitalize on the efficiency push. Additionally, sectors like management consulting could see increased demand as agencies seek help navigating the cuts.
Related News
Stock market today: S&P 500, Nasdaq edge higher with fresh tariffs, Fed minutes in focus
Feb 19, 2025, 2:13 PM
Investors are weighing Trump's latest tariff salvo and waiting for Fed minutes for insight into future policy.
Stock market today: Dow, S&P 500, Nasdaq jump as Nvidia, Tesla lead spark to end losing week
Jan 3, 2025, 4:05 PM
Hopes are dim for a "Santa Claus" rally after a five-session run of losses for the S&P 500.
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next
Dec 19, 2024, 3:57 PM
The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.